| Related Articles |
Amphetamine/Dextroamphetamine Salts for Delayed Orgasm and Anorgasmia in Men: A Pilot Study.
Urology. 2020 Apr 30;:
Authors: Levine LA, Betcher HK, Ziegelmann MJ, Bajic P
Abstract
OBJECTIVES: To describe our experience with amphetamine/dextroamphetamine salts (AMP) as a treatment for DO/AO.
METHODS: We identified patients with DO/AO from 9/2017-9/2019. Baseline characteristics and patient-reported orgasmic latency time (OLT) were recorded. After extensive screening, patients were treated with AMP. Validated questionnaires were administered including International Index of Erectile Function-5, quantitative Androgen Deficiency in the Aging Male and Adult ADHD Self-Report Scale. OLT change, adverse effects and patient satisfaction were assessed. Baseline characteristics were compared using chi-squared test. OLT changes were compared with one-way ANOVA. Multivariable logistic regression was performed to identify predictors of treatment success. P<0.05 was statistically significant.
RESULTS: 17 men received AMP-6/17(35.3%) for AO and 11/17(64.7%) for DO, with median follow-up 1.0yr (IQR 1.0 yrs). Amongst responders, AMP improved subjective experience of sex in 8/17 (47.1%) patients (2/6 with AO). Of those, 6/17(35.3%; 1/6 with AO) experienced reduced OLT or increased frequency of orgasm. Non-responders were older than responders, with median age 69.5(IQR 4.3) vs. 61.0yrs (IQR 12.3; p=0.024). There were no other significant differences in baseline characteristics among responders. 6/8(75%) responders and 8/9(88.9%) non-responders failed other treatment modalities prior to AMP. Among responders with DO and improved OLT, mean OLT decreased by 72.3%(40.7 to 11.1 minutes, p=0.049) for intercourse. Minimal side effects were noted including insomnia and jitters in one patient each.
CONCLUSIONS: AMP as a treatment for AO/DO merits further investigation. Measurable improvements in OLT or frequency of orgasm occurred in >1/3 of patients. Larger prospective multi-center studies with strict inclusion/exclusion criteria are warranted.
PMID: 32360625 [PubMed – as supplied by publisher]
via https://www.ncbi.nlm.nih.gov/pubmed/32360625?dopt=Abstract
